FinSME Article Discusses Gallant’s Series A Funding
by Gallant Staff
Read FinSME’s coverage of our Series A funding, which will help us advance our pipeline of off-this-shelf stem cell therapies for pets.
From FinSMEs
Gallant Therapeutics Raises Over $15M in Series A Funding
